New blood product tested for safer liver transplants

NCT ID NCT07265843

Not yet recruiting Disease control Sponsor: Trauma Hemostatis and Oxygenation Research (THOR) Network Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two blood products used to control bleeding during liver transplant surgery. It compares a newer product, Intercept Fibrinogen Complex, to standard cryoprecipitate. The goal is to see if the newer product works as well or better at stopping bleeding. The study will involve 60 adults scheduled for a liver transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Intercept Fibrinogen Complex (IFC) and Cryoprecipitate Antihemophilic Factor (AHF)
What this could lead to: If successful, this could show that the newer blood product is a safe and effective option for controlling bleeding during liver transplant, potentially improving access and outcomes.
What could go wrong: This is a small, early pilot study with only 60 participants, so results may not apply to all patients. There is also a risk of allergic reactions or other complications from blood products.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver hepatitis C virus infection metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER TRANSPLANT SURGERY

Contacts and locations

Locations

University of Cincinnati

Cincinnati, Ohio, 45221, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.